ReviewCureus2026
Regenerative Trifecta: A Multimodal Regenerative Approach to Soft Tissue Injury Recovery and Return to Sport.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft tissue injuries - affecting tendons, ligaments, and muscles - are the leading cause of missed games, lost seasons, and early career endings in competitive sports. Injury rates across major professional leagues have risen significantly over the past decade, with the knee, groin, hip, and thigh bearing the greatest burden. The financial impact is enormous at the high school and collegiate levels alone, while at the professional level, soft tissue failures have decided playoff outcomes and derailed championship-caliber teams. Standard treatments - rest, physical therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids - address symptoms but not the underlying biology. Tendons and ligaments are poorly vascularized structures that heal through fibrotic scar tissue rather than true collagen restoration, leaving repaired tissue mechanically weak and prone to re-injury. Regenerative medicine offers a fundamentally different approach. Mesenchymal stem cells (MSCs), platelet-rich plasma (PRP), and extracellular vesicles (EVs) actively remodel the injury environment, promoting improved healing quality and reduced scar formation compared to standard care. Clinical evidence from randomized controlled trials and meta-analyses demonstrates that PRP accelerates return-to-sport timelines in acute muscle injuries , while preclinical and early translational evidence supports MSC and EV therapy for improving healing quality. This paper reviews the evidence for regenerative biologics in sports medicine and presents the Regenerative Trifecta protocol developed by R3 Stem Cell, one of the world's largest multinational regenerative networks. It is a coordinated combination of umbilical cord mesenchymal stem cells (UC-MSCs), PRP, and exosomes designed to address the full biology of soft tissue healing. The mechanism of each component is described along with the clinical data supporting its use, and the rationale for multi-modal over single-modality treatment, with particular attention to elite and masters athlete populations where healing biology and clinical need converge most critically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.